A  ||| S:0 E:2 ||| DT
systematic  ||| S:2 E:13 ||| JJ
comparison  ||| S:13 E:24 ||| NN
of  ||| S:24 E:27 ||| IN
rheumatoid  ||| S:27 E:38 ||| JJ
arthritis  ||| S:38 E:48 ||| NN
and  ||| S:48 E:52 ||| CC
ankylosing  ||| S:52 E:63 ||| JJ
spondylitis ||| S:63 E:74 ||| NN
:  ||| S:74 E:76 ||| :
non-steroidal  ||| S:76 E:90 ||| JJ
anti-inflammatory  ||| S:90 E:108 ||| JJ
drugs  ||| S:108 E:114 ||| NNS
Non-steroidal  ||| S:114 E:128 ||| JJ
anti-inflammatory  ||| S:128 E:146 ||| JJ
drugs  ||| S:146 E:152 ||| NNS
( ||| S:152 E:153 ||| -LRB-
NSAIDs ||| S:153 E:159 ||| NNP
)  ||| S:159 E:161 ||| -RRB-
play  ||| S:161 E:166 ||| VBP
different  ||| S:166 E:176 ||| JJ
roles  ||| S:176 E:182 ||| NNS
in  ||| S:182 E:185 ||| IN
the  ||| S:185 E:189 ||| DT
management  ||| S:189 E:200 ||| NN
of  ||| S:200 E:203 ||| IN
patients  ||| S:203 E:212 ||| NNS
with  ||| S:212 E:217 ||| IN
rheumatoid  ||| S:217 E:228 ||| JJ
arthritis  ||| S:228 E:238 ||| NN
( ||| S:238 E:239 ||| -LRB-
RA ||| S:239 E:241 ||| NNP
)  ||| S:241 E:243 ||| -RRB-
and  ||| S:243 E:247 ||| CC
ankylosing  ||| S:247 E:258 ||| JJ
spondylitis  ||| S:258 E:270 ||| NNS
( ||| S:270 E:271 ||| -LRB-
AS ||| S:271 E:273 ||| NNP
) ||| S:273 E:274 ||| -RRB-
.  ||| S:274 E:276 ||| .
In  ||| S:276 E:279 ||| IN
RA  ||| S:279 E:282 ||| NNP
there  ||| S:282 E:288 ||| EX
is  ||| S:288 E:291 ||| VBZ
minimal  ||| S:291 E:299 ||| JJ
evidence  ||| S:299 E:308 ||| NN
that  ||| S:308 E:313 ||| IN
NSAIDs  ||| S:313 E:320 ||| NNS
are  ||| S:320 E:324 ||| VBP
able  ||| S:324 E:329 ||| JJ
to  ||| S:329 E:332 ||| TO
alter  ||| S:332 E:338 ||| VB
the  ||| S:338 E:342 ||| DT
course  ||| S:342 E:349 ||| NN
of  ||| S:349 E:352 ||| IN
disease  ||| S:352 E:360 ||| NN
or  ||| S:360 E:363 ||| CC
prevent  ||| S:363 E:371 ||| VB
joint  ||| S:371 E:377 ||| JJ
destruction  ||| S:377 E:389 ||| NN
and ||| S:389 E:392 ||| CC
,  ||| S:392 E:394 ||| ,
therefore ||| S:394 E:403 ||| RB
,  ||| S:403 E:405 ||| ,
they  ||| S:405 E:410 ||| PRP
should  ||| S:410 E:417 ||| MD
mostly  ||| S:417 E:424 ||| RB
be  ||| S:424 E:427 ||| VB
used  ||| S:427 E:432 ||| VBN
as  ||| S:432 E:435 ||| IN
a  ||| S:435 E:437 ||| DT
short-term  ||| S:437 E:448 ||| JJ
bridging  ||| S:448 E:457 ||| JJ
therapy ||| S:457 E:464 ||| NN
.  ||| S:464 E:466 ||| .
In  ||| S:466 E:469 ||| IN
contrast  ||| S:469 E:478 ||| NN
to  ||| S:478 E:481 ||| TO
RA ||| S:481 E:483 ||| NNP
,  ||| S:483 E:485 ||| ,
in  ||| S:485 E:488 ||| IN
AS  ||| S:488 E:491 ||| NNP
NSAIDs  ||| S:491 E:498 ||| NNP
are  ||| S:498 E:502 ||| VBP
considered  ||| S:502 E:513 ||| VBN
as  ||| S:513 E:516 ||| IN
a  ||| S:516 E:518 ||| DT
cornerstone  ||| S:518 E:530 ||| NN
of  ||| S:530 E:533 ||| IN
the  ||| S:533 E:537 ||| DT
treatment  ||| S:537 E:547 ||| NN
not  ||| S:547 E:551 ||| RB
only  ||| S:551 E:556 ||| RB
because  ||| S:556 E:564 ||| IN
of  ||| S:564 E:567 ||| IN
a  ||| S:567 E:569 ||| DT
high  ||| S:569 E:574 ||| JJ
symptomatic  ||| S:574 E:586 ||| JJ
efficacy ||| S:586 E:594 ||| NN
,  ||| S:594 E:596 ||| ,
but  ||| S:596 E:600 ||| CC
also  ||| S:600 E:605 ||| RB
because  ||| S:605 E:613 ||| IN
they  ||| S:613 E:618 ||| PRP
might  ||| S:618 E:624 ||| MD
even  ||| S:624 E:629 ||| RB
retard  ||| S:629 E:636 ||| JJ
osteoproliferation  ||| S:636 E:655 ||| NN
and  ||| S:655 E:659 ||| CC
radiographic  ||| S:659 E:672 ||| JJ
progression ||| S:672 E:683 ||| NN
.  ||| S:683 E:685 ||| .
Considering  ||| S:685 E:697 ||| VBG
younger  ||| S:697 E:705 ||| JJR
age  ||| S:705 E:709 ||| NN
of  ||| S:709 E:712 ||| IN
AS  ||| S:712 E:715 ||| NNP
patients  ||| S:715 E:724 ||| NNS
and  ||| S:724 E:728 ||| CC
lower  ||| S:728 E:734 ||| JJR
prevalence  ||| S:734 E:745 ||| NN
of  ||| S:745 E:748 ||| IN
comorbidities ||| S:748 E:761 ||| NN
,  ||| S:761 E:763 ||| ,
they  ||| S:763 E:768 ||| PRP
are  ||| S:768 E:772 ||| VBP
probably  ||| S:772 E:781 ||| RB
at  ||| S:781 E:784 ||| IN
lower  ||| S:784 E:790 ||| JJR
risk  ||| S:790 E:795 ||| NN
for  ||| S:795 E:799 ||| IN
cardiovascular  ||| S:799 E:814 ||| JJ
and  ||| S:814 E:818 ||| CC
gastrointestinal  ||| S:818 E:835 ||| JJ
side  ||| S:835 E:840 ||| NN
effects  ||| S:840 E:848 ||| NNS
of  ||| S:848 E:851 ||| IN
short-  ||| S:851 E:858 ||| JJ
and  ||| S:858 E:862 ||| CC
long-term  ||| S:862 E:872 ||| JJ
NSAID  ||| S:872 E:878 ||| NNP
therapy  ||| S:878 E:886 ||| NN
in  ||| S:886 E:889 ||| IN
comparison  ||| S:889 E:900 ||| NN
to  ||| S:900 E:903 ||| TO
RA ||| S:903 E:905 ||| NNP
.  ||| S:905 E:907 ||| .
